首页> 外文期刊>Internal medicine. >Circulating levels of soluble Fas ligand in cachexic patients with COPD are higher than those in non-cachexic patients with COPD.
【24h】

Circulating levels of soluble Fas ligand in cachexic patients with COPD are higher than those in non-cachexic patients with COPD.

机译:COPD恶病质患者的可溶性Fas配体循环水平高于非恶病质COPD患者。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: Apoptosis may be involved in the pathophysiology of cachexia in patients with chronic obstructive pulmonary disease (COPD). The purpose of this study is to assess the potential role of the Fas-Fas ligand (FasL) system in cachexic patients with COPD. PATIENTS AND METHODS: We measured the circulating levels of soluble FasL (sFasL), with a newly developed, highly sensitive enzyme-linked immunosorbent assay system in seventy patients with COPD and forty-seven control subjects. RESULTS: The levels of sFasL in the COPD patients were significantly lower than those in the control subjects (46+/-29 vs. 55+/-28 pg/ml; p<0.05), whereas the levels of soluble Fas (sFas) remained unchanged between the two groups. The significant correlation between the levels of sFasL and sFas, observed in the control subjects (r=0.304; p<0.05), was absent in the COPD patients. Cachexic COPD patients with a relatively lower BMI (BMI <20 kg/m(2), n=45) and %fat (%fat <20%, n=34), showed significantly increased levels of sFasL compared to non-cachexic COPD patients with a relatively higher BMI (BMI > or =20 kg/m(2), n=25) and %fat (%fat > or =20%, n=36) (BMI; 51+/-33 vs. 36+/-15 pg/ml; p<0.05. %fat; 55+/-33 vs. 37+/-21 pg/ml; p<0.01), due to the inverse relationships between the body composition measurements and the levels of sFasL observed exclusively in the patients (BMI; r=-0.307; p<0.05. %fat; r=-0.283; p<0.05). CONCLUSION: These results may suggest that the Fas-FasL system does not play a significant role in the potential triggers of enhanced apoptosis leading to skeletal muscle wasting and adipose tissue depletion in cachexic patients with COPD.
机译:目的:细胞凋亡可能与慢性阻塞性肺疾病(COPD)患者恶病质的病理生理有关。这项研究的目的是评估Fas-Fas配体(FasL)系统在慢性阻塞性肺病患者中的潜在作用。患者和方法:我们使用新开发的高度敏感的酶联免疫吸附测定系统,对70例COPD患者和47例对照受试者的可溶性FasL(sFasL)循环水平进行了测量。结果:COPD患者的sFasL水平显着低于对照组(46 +/- 29 vs. 55 +/- 28 pg / ml; p <0.05),而可溶性Fas(sFas)水平两组之间保持不变。在COPD患者中没有观察到在对照受试者中观察到的sFasL和sFas水平之间的显着相关性(r = 0.304; p <0.05)。 BMI(BMI <20 kg / m(2),n = 45)和%fat(%fat <​​20%,n = 34)相对较低的Cachexic COPD患者与非Cachedic COPD相比,sFasL水平显着增加BMI相对较高(BMI>或= 20 kg / m(2),n = 25)和%fat(%fat>或= 20%,n = 36)的患者(BMI; 51 +/- 33 vs. 36 +/- 15 pg / ml; p <0.05。%fat; 55 +/- 33 vs. 37 +/- 21 pg / ml; p <0.01),这是由于身体成分测量值与脂肪水平之间的反比关系仅在患者中观察到sFasL(BMI; r = -0.307; p <0.05。%脂肪; r = -0.283; p <0.05)。结论:这些结果可能表明,Fas-FasL系统在潜在的引发凋亡增加的潜在触发因素中不发挥重要作用,导致细胞凋亡,从而导致慢性阻塞性肺病的慢性阻塞性肺病患者骨骼肌消耗和脂肪组织消耗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号